E-cigarette effectiveness in smoking cessation

Nov.21.2022
E-cigarette effectiveness in smoking cessation
A study by the UK Cochrane Group found that nicotine e-cigarettes can improve smoking cessation rates.

Recently, the UK-based Cochrane Collaboration conducted 78 studies involving 22,052 smokers, comparing the use of electronic cigarettes with the following factors:


Nicotine replacement therapy (such as patches or gum);


Varenicline, a medication that helps people quit smoking;


Nicotine-free electronic cigarette;


Other types of electronic cigarettes that contain nicotine (such as pods);


Actions of support, such as advice or consultation.


The research was mostly conducted in the United States (34 studies), United Kingdom (16 studies), and Italy (8 studies).


Key Conclusion


Using nicotine-containing e-cigarettes is more effective than using nicotine replacement therapy or non-nicotine e-cigarettes for quitting smoking. The most common adverse effects of using e-cigarettes with nicotine are throat or oral irritation, headaches, coughing and nausea. As people continue to use nicotine e-cigarettes, these effects become lessened over time.


Research summary


There is strong evidence to suggest that nicotine-containing e-cigarettes are more effective for smoking cessation than NRT, while moderate quality evidence suggests that nicotine-containing e-cigarettes are more effective for smoking cessation than non-nicotine e-cigarettes. Comparing nicotine replacement therapy to standard care or no treatment also shows benefit, but with lower certainty and requiring further research to confirm the effect. In most cases, the confidence intervals for data on AEs, SAEs, and other safety indicators are broad, with no differences observed between nicotine and non-nicotine e-cigarettes in terms of AEs, or between nicotine e-cigarettes and NRT. The overall incidence rate of SAEs was low across all study groups. No evidence was found for serious harm from nicotine e-cigarettes, but the longest follow-up period was two years and the number of studies was limited. The primary limitation of the evidence base continues to be imprecision due to limited numbers of RCTs and typically low event rates, but further RCTs are currently ongoing. To ensure that this review continues to provide up-to-date information for decision-makers, it is a living system review. Searches are conducted monthly and the review is updated when new relevant evidence becomes available. Please refer to the Cochrane Systematic Reviews Database for the current status of this review.


Statement:


This article is based on third-party information that has been edited by machine translation, and is only intended for industry communication and learning purposes.


This article does not represent the views of 2FIRSTS and 2FIRSTS cannot confirm the truthfulness or accuracy of the article's content. The translation of this article is only for the purpose of industry-related communication and research.


Due to limitations in the translator's abilities, the translated article may not fully express the original content. Please refer to the original article for accuracy.


2FIRSTS maintains complete alignment with the Chinese government in regards to any domestic, Hong Kong, Macau, Taiwan, or international statements and positions.


The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us to have it removed.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Argentina’s New Nicotine Rules Draw Cautious Optimism and Market Concerns, Local Tobacco Harm Reduction Advocate Says
Argentina’s New Nicotine Rules Draw Cautious Optimism and Market Concerns, Local Tobacco Harm Reduction Advocate Says
Argentina’s new tobacco and nicotine framework marks a shift from prohibition toward registration, traceability and health surveillance. Argentine THR advocate Juan Facundo Teme told 2Firsts that adult consumers and parts of the local commercial sector are cautiously optimistic, but concerns remain over flavor limits, registration costs and market access. The policy’s implementation may determine whether Argentina can move informal sales into regulated channels.
May.11
CBP and FDA Seize 18 Million Illegal Vapes Worth $175 Million in Maritime Cargo Operation
CBP and FDA Seize 18 Million Illegal Vapes Worth $175 Million in Maritime Cargo Operation
U.S. Customs and Border Protection (CBP) announced that more than 18 million illegal e-cigarettes valued at over $175 million were seized during “Operation Red Mist,” a joint enforcement initiative involving the U.S. Coast Guard and the FDA. The operation primarily targeted maritime vape shipments originating from China and focused on combating illicit importation, transportation, and distribution activities.
Regulations
May.14
LOST MARY Launches VIZ With Transparent Wraparound Pod and LED Display
LOST MARY Launches VIZ With Transparent Wraparound Pod and LED Display
LOST MARY announced VIZ on May 6, 2026, describing it as the brand’s first product with a transparent 360-degree wraparound pod.
May.07 by 2FIRSTS.ai
FDA Tobacco Center Plans Faster Review Process for Certain Supplemental PMTAs
FDA Tobacco Center Plans Faster Review Process for Certain Supplemental PMTAs
FDA Center for Tobacco Products Acting Director Bret Koplow issued a statement on May 7 outlining new steps to accelerate tobacco product premarket application review. The statement said CTP reduced the backlog of applications by approximately 70% in 2025 and that there is no longer a queue for PMTAs pending acceptance review.
May.09 by 2FIRSTS.ai
Trump Reportedly Signs Off on Plan to Fire FDA Commissioner Marty Makary
Trump Reportedly Signs Off on Plan to Fire FDA Commissioner Marty Makary
According to The Wall Street Journal, people familiar with the matter said President Trump has signed off on a plan to fire FDA Commissioner Marty Makary, though the plan is not yet final and could change. The report said Makary’s tenure has included clashes over vaping, abortion and drug policy, and that some senior administration officials view him as struggling to manage the agency.
May.09 by 2FIRSTS.ai
2Firsts Exclusive Analysis | RLX Q1 Revenue Rises 96.2%, International Business Points to a More Integrated Global Strategy
2Firsts Exclusive Analysis | RLX Q1 Revenue Rises 96.2%, International Business Points to a More Integrated Global Strategy
RLX Technology’s Q1 net revenues rose 96.2% year over year, with international business accounting for 72.3% of total revenue. Beyond the headline growth, the results point to deeper globalization: European operations, Nexus supply-chain integration and a broader product portfolio are becoming key signals to watch.
Special Report
May.20